Skip to Main Content

Personalized vaccines for a type of brain cancer mounted an immune system response against the tumors in a small number of patients, according to data from two new studies, an early indication that immunotherapy might hold some promise for targeting the difficult-to-treat cancers.

The studies, published Wednesday in the journal Nature, underscore how wily glioblastoma, or GBM, is in evading attacks by the immune system on tumors: The patients did not see the course of their disease change, and even patients who generated an immune response died from their cancers.


Still, experts said, the early-stage clinical trials suggest researchers may be able to find ways to improve immunotherapies and the ways in which they are delivered to develop effective cancer vaccines.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!